{"doi":"10.1215/s1152851703000309","title":"Phase 2 study of BCNU and temozolomide for recurrent glioblastoma\nmultiforme: North American Brain Tumor Consortium study","abstract":null,"journal":"Neuro-Oncology","year":2004,"id":637416,"datarank":0.6329261557764161,"base_score":4.219507705176107,"endowment":4.219507705176107,"self_citation_contribution":0.6329261557764161,"citation_network_contribution":0.0,"self_endowment_contribution":0.6329261557764161,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":67,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":897054,"name":"W.K. Alfred Yung","orcid":"0000-0002-1669-0793","position":1,"is_corresponding":false},{"id":251175,"name":"Howard A. Fine","orcid":"0000-0002-6169-5702","position":2,"is_corresponding":false},{"id":1655088,"name":"Harry S. Greenberg","orcid":null,"position":3,"is_corresponding":false},{"id":225604,"name":"Larry Junck","orcid":"0000-0002-8203-0400","position":4,"is_corresponding":false},{"id":133421,"name":"Susan M. Chang","orcid":null,"position":5,"is_corresponding":false},{"id":1119462,"name":"M. Kelly Nicholas","orcid":null,"position":6,"is_corresponding":false},{"id":133424,"name":"H. Ian Robins","orcid":null,"position":7,"is_corresponding":false},{"id":259435,"name":"Minesh P. Mehta","orcid":"0000-0002-4812-5713","position":8,"is_corresponding":false},{"id":133427,"name":"Karen L. Fink","orcid":null,"position":9,"is_corresponding":false},{"id":273497,"name":"Kurt A. Jaeckle","orcid":"0000-0002-7827-463X","position":10,"is_corresponding":false},{"id":1655098,"name":"John Kuhn","orcid":null,"position":11,"is_corresponding":false},{"id":236013,"name":"Kenneth R. Hess","orcid":"0000-0003-1377-6070","position":12,"is_corresponding":false},{"id":1655100,"name":"S. Clifford Schold","orcid":null,"position":13,"is_corresponding":false},{"id":32675,"name":"Michael D. Prados","orcid":"0000-0002-9630-2075","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Phase 2 study of BCNU and temozolomide for recurrent glioblastoma\nmultiforme: North American Brain Tumor Consortium study","abstract":"The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme. The phase 2 dose and schedule for this trial was BCNU 150 mg/m(2) i.v. followed in 2 h by temozolomide 550 mg/m(2) as a single oral dose. Treatment was repeated every 6 weeks for up to 8 cycles unless tumor progression was documented. The primary end point was PFS at 6 months (PFS-6). Response was a secondary end point, measured by MR imaging, neurological status, and steroid requirements prior to each 6-week cycle. The median age of eligible patients was 53, and 89.5% had no prior chemotherapy. All patients were evaluable for toxicity and time to progression. The PFS-6 was 21%. Overall survival was 68% at 6 months and 26% at 1 year. The MRI response for 36 patients was 2 partial responses, 2 minor responses, 19 cases of stable disease, and 13 immediate progressions. Median survival was 34 weeks, and median PFS was 11 weeks. Toxicity was primarily myelosuppression; no toxic deaths occurred. Historical phase 2 study data in this patient population show a PFS-6 of 15%. Recent data for use of temozolomide alone have shown a PFS-6 of 21%. We conclude that BCNU plus temozolomide when used in these doses and schedule has only modest activity, with significant toxicity, and appears to be no more effective than single-agent temozolomide.","is_dataset_classified":null,"base_score":4.219507705176107,"endowment":4.219507705176107,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"14769138","pmcid":"PMC1871975","openalex_id":"https://openalex.org/W2123133319","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"CA62421","title":null},{"funder_name":"NCI NIH HHS","grant_id":"CA62422","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"M01 RR000042","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"M01 RR000633","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"M01-RR03186","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"M01 RR000056","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U01 CA062412","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U01 CA062407","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"M01 RR003186","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"M01-RR00042","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U01 CA062399","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U01 CA062426","title":null},{"funder_name":"NCI NIH HHS","grant_id":"CA62407","title":null},{"funder_name":"NCI NIH HHS","grant_id":"CA62455","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U01 CA062422","title":null},{"funder_name":"NCI NIH HHS","grant_id":"CA62405","title":null},{"funder_name":"NCI NIH HHS","grant_id":"CA62412","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"M01 RR000079","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"M01-RR00079","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U01 CA062421","title":null},{"funder_name":"NCI NIH HHS","grant_id":"CA62399","title":null},{"funder_name":"NCI NIH HHS","grant_id":"CA62426","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"M01-RR00056","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"M01-RR00633","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U01 CA062405","title":null}],"total_grants":25,"fwci":5.0386,"citation_percentile":0.95959329,"influential_citations":0,"citation_trend":[{"year":2013,"count":2},{"year":2014,"count":4},{"year":2015,"count":2},{"year":2016,"count":5},{"year":2017,"count":5},{"year":2019,"count":1},{"year":2022,"count":1},{"year":2023,"count":1},{"year":2024,"count":2}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"https://academic.oup.com/neuro-oncology/article-pdf/6/1/33/13066030/06_NO6.1Prados.pdf","host_type":"journal"},{"url":"https://academic.oup.com/neuro-oncology/article-pdf/6/1/33/13066030/06_NO6.1Prados.pdf","host_type":"publisher"},{"url":"http://academic.oup.com/neuro-oncology/article-pdf/6/1/33/13066030/06_NO6.1Prados.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1215/s1152851703000309","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/14769138","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/1871975","host_type":"repository"}],"fields_of_study":["Glioma Diagnosis and Treatment","Brain Metastases and Treatment","Nanoplatforms for cancer theranostics","Adult","Aged","Antineoplastic Combined Chemotherapy Protocols","Brain Neoplasms","Carmustine","Confidence Intervals","Dacarbazine","Disease-Free Survival","Female","Glioblastoma","Humans","Male","Middle Aged","Neoplasm Recurrence, Local","North America","Temozolomide"],"mesh_terms":["Temozolomide","Adult","Aged","Antineoplastic Combined Chemotherapy Protocols","Brain Neoplasms","Carmustine","Dacarbazine","Female","Glioblastoma","Humans","Male","Middle Aged","Neoplasm Recurrence, Local","North America","Confidence Intervals","Disease-Free Survival"],"keywords":["Temozolomide","Medicine","Dacarbazine","Toxicity","Phases of clinical research","Internal medicine","Progression-free survival","Clinical endpoint","Chemotherapy","Oncology","Carmustine","Population","Surgery","Clinical trial","Cyclophosphamide"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T18:54:09.707676Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}